mefloquine has been researched along with nisoldipine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Rustenbeck, I; Seemann, N; Welling, A | 1 |
1 review(s) available for mefloquine and nisoldipine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for mefloquine and nisoldipine
| Article | Year |
|---|---|
The inhibitor of connexin Cx36 channels, mefloquine, inhibits voltage-dependent Ca
Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester; Action Potentials; Animals; Calcium; Calcium Channel Blockers; Calcium Channels; Connexins; Dihydropyridines; Gap Junction delta-2 Protein; Glucose; Insulin Secretion; Insulin-Secreting Cells; Ion Channel Gating; Mefloquine; Mice; Nisoldipine; Potassium Chloride; Tolbutamide | 2018 |